A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery

Phase 3

Active, not recruiting

• Conditions: Melanoma
• Interventions: Drug: Fianlimab; Drug: Pembrolizumab; Drug: Cemiplimab; Drug: Placebo

• Registration Number: NCT05608291
• Lead Sponsor: Regeneron Pharmaceuticals

Brief Summary

This study is researching an experimental drug called REGN3767, also known as fianlimab (R3767), when combined with another medication called cemiplimab (each individually called a "study drug" or called "study drugs" when combined) compared with an approved medication called pembrolizumab.

The objective of this study is to see if the combination of fianlimab and cemiplimab is an effective treatment compared to pembrolizumab in patients that have had melanoma removal surgery but are still at high risk for the recurrence of the disease. Pembrolizumab is an approved treatment in some countries in this clinical setting.

The study is looking at several other research questions, including:

* What side effects may happen from receiving the study drugs.

* How much study drug is in the blood at different times.

* Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects). Antibodies are proteins that are naturally found in the blood stream that fight infections.

* How administering the study drugs might improve quality of life.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2022-10-14
• Study First Submitted QC: 2022-10-31
• Study First Posted: 2022-11-08
• Study Start: 2023-01-16
• Status Verified: 2025-05
• Last Update Submitted: 2025-05-12
• Last Update Posted: 2025-05-13
• Primary Completion: 2028-05-16
• Study Completion: 2030-02-15

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: All
• Target Recruitment: 1564

Inclusion Criteria

1. All patients must be either stage IIB, IIC, III, or stage IV per American Joint Committee on Cancer (AJCC) 8th edition and have histologically confirmed melanoma that is completely surgically resected in order to be eligible as defined by the protocol
2. Complete surgical resection must be performed within 12 weeks prior to randomization, and enrollment may occur only after satisfactory wound healing from the surgery
3. All patients must have disease-free status documented by a complete physical examination and imaging studies within 4 weeks prior to randomization, as described in the protocol

Key

Exclusion Criteria

1. Uveal melanoma
2. Any evidence of residual disease after surgery by imaging, pathology, or cytology.
3. Ongoing or recent (within 2 years) evidence of clinically significant autoimmune disease that required treatment
4. Uncontrolled infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C (HCV) infection; or diagnosis of immunodeficiency that is related to, or results in chronic infection, as described in the protocol
5. Another malignancy that is currently progressing or that required active treatment in the past 5 years, as described in the protocol
6. Participants with a history of myocarditis
7. Adolescent patients (≥12 to <18 years old) with body weight <40 kg

Note: Other Protocol Defined Inclusion/ Exclusion Criteria Apply

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Fianlimab HD + Cemiplimab	Fianlimab	Patients will be administered one combination dose of fianlimab high dose (HD) and cemiplimab
Fianlimab HD + Cemiplimab	Cemiplimab	Patients will be administered one combination dose of fianlimab high dose (HD) and cemiplimab
Fianlimab LD + Cemiplimab	Fianlimab	Patients will be administered one combination dose of fianlimab low dose (LD) and cemiplimab
Fianlimab LD + Cemiplimab	Cemiplimab	Patients will be administered one combination dose of fianlimab low dose (LD) and cemiplimab
Pembrolizumab	Pembrolizumab	Patients will be administered one dose of pembrolizumab co-infused with saline/dextrose placebo
Pembrolizumab	Placebo	Patients will be administered one dose of pembrolizumab co-infused with saline/dextrose placebo

Primary Outcome Measures

Name	Time	Method
Relapse free survival (RSF)	Up to 5 Years	Time from randomization to the first documented recurrence of disease at any site (excluding new primary melanomas) or death from any cause, whichever occurs first.

Secondary Outcome Measures

Name	Time	Method
Distant metastasis-free survival (DMFS)	Up to 5 Years	Time between the date of randomization and the date of the first distant metastasis.
Occurrence of immune-mediated EAEs (im-EAEs)	Up to 5 Years	imAEs are a unique set of toxicities thought to be caused by unrestrained cellular immune responses.
Overall survival (OS)	Up to 5 Years	Time from randomization to the date of death.
Occurrence of treatment-emergent adverse events (TEAEs)	Up to 5 Years	A TEAE is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment.
Occurrence of serious adverse events (SAEs)	Up to 5 Years	An SAE is any untoward medical occurrence that at any dose: * Results in death - includes all deaths, even those that appear to be completely unrelated to study drug (eg, a car accident in which a patient is a passenger).; * Is life-threatening; * Requires in-patient hospitalization or prolongation of existing hospitalization.; * Results in persistent or significant disability/incapacity; * Is a congenital anomaly/birth defect.; * Is an important medical event
Occurrence of adverse events of special interest (AESIs)	Up to 5 Years	An AESI (serious or non-serious) is one of scientific and medical concern specific to the sponsor's product or program, for which ongoing monitoring and rapid communication by the Investigator to the sponsor can be appropriate. Such an event might warrant further investigation in order to characterize and understand it
Occurrence of laboratory abnormalities	Up to 5 Years	As assessed by the NCI-CTCAE grading system (≥ Grade 3 or higher)
Concentrations of fianlimab in serum over time	Up to 5 Years	The concentrations of fianlimab over time will be summarized by descriptive statistics by study arm for the overall population and for adolescent patients.
Patient report outcomes (PRO) for adults as measured by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)	Up to 5 Year	The EORTC QLQ-C30 (Version 3) uses for the questions 1 to 28 a 4-point scale. The scale scores from 1 to 4: 1 ("Not at all"), 2 ("A little"), 3 ("Quite a bit") and 4 ("Very much"). Half points are not allowed. The range is 3. For the raw score, less points are considered to have a better outcome.; The EORTC QLQ-C30 (Version 3) uses for the questions 29 and 30 a 7-points scale. The scale scores from 1 to 7: 1 ("very poor") to 7 ("excellent"). Half points are not allowed. The range is 6. More points are considered to have a better outcome.
PRO for adults as measured by the European Quality of Life Dimension 5 (EQ-5D-5L)	Up to 5 Years	The EQ-5D-5L a descriptive system that comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions. This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state.
PRO for adults as determined by the Patient Global Impressions Scale (PGIS)	Up to 5 Years	The PGIS is a single 1-item questionnaire designed to assess participant's overall impression of disease severity at a given point in time by using a 4-point Likert scale that ranges from (1) = "none (no symptoms)" to (4) = "severe".
Time to physical functioning deterioration per EORTC QLQ-C30	Up to 5 Years
Occurrence of TEAEs resulting in death	Up to 5 Years	A TEAE resulting in death is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment.
Occurrence of dose-limiting toxicity (DLT)	Up to 5 Years	A DLT is defined as a study-drug related TEAE, including imAEs, that could preclude enrolling additional adolescent patients at the selected dose. Dose-limiting toxicity will be evaluated in adolescents only.
Occurrence of interruption or discontinuation of study drug(s) due to TEAE	Up to 5 Years	A TEAE is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment.
Concentrations of cemiplimab in serum over time	Up to 5 Years	The concentrations of cemiplimab over time will be summarized by descriptive statistics by study arm for the overall population and for adolescent patients.
Concentration of finalimab anti-drug antibodies (ADA) and neutralizing antibodies	Up to 5 Years	Immunogenicity will be characterized per drug molecule by ADA and NAb status.
Concentration of cemiplimab anti-drug antibodies (ADA) and neutralizing antibodies	Up to 5 Years	Immunogenicity will be characterized per drug molecule by ADA and NAb status.
PRO for adults as determined by the Patient Global Impressions of Change Scale (PGIC)	Up to 5 Years	The PGIC is a single-item questionnaire designed to assess the participant's overall sense of whether there has been a change since starting treatment as rated on a 5-point Likert scale anchored by (1) "much better" to (5) "much worse", with (4) = "no change".
Time to global health status/quality of life deterioration per EORTC QLQ-C30	Up to 5 years
PRO for adults as measured by the Functional Assessment of Cancer Therapy (FACT) - melanoma	Up to 5 Years	The FACT-M is a melanoma-specific quality of life questionnaire that is composed of items from the Functional Assessment of Cancer Therapy-General (FACT-G). The FACT-M is scored on a 5 point Likert-scale: "Not at all", "A little bit", "Somewhat", "Quite a bit", and "Very much.". A Higher score represents higher Health Related Quality of Life (HRQoL).
Time to role functioning deterioration per EORTC QLQ-C30	Up to 5 Years

Trial Locations

Locations (211)

Sainte Catherine Institut du Cancer Avignon Provence; 🇫🇷 Avignon, France

N_Hôpital Ambroise-Paré; 🇫🇷 Boulogne Billancourt, France

CHU Estaing; 🇫🇷 Clermont Ferrand, France

Incliva - Instituto de Investigacion Sanitaria; 🇪🇸 Valencia, Spain

Baskent University; 🇹🇷 Yuregir, Adana, Turkey

Dicle University - Medical Faculty Campus; 🇹🇷 Sur, Diyarbakir, Turkey

Kocaeli University; 🇹🇷 İzmit, Kocaeli, Turkey

BioClinic Thessaloniki; 🇬🇷 Thessaloniki, Greece

Interbalkan Medical Center; 🇬🇷 Thessaloniki, Greece

UCK; 🇵🇱 Gdansk, Pomerania, Poland

Instituto Valenciano de Oncologia; 🇪🇸 Valencia, Spain

UC San Diego; 🇺🇸 La Jolla, California, United States

UCSF Medical Center at Mission Bay; 🇺🇸 San Francisco, California, United States

John Wayne Cancer Institute (JWCI); 🇺🇸 Santa Monica, California, United States

The Melanoma And Skin Cancer Institute; 🇺🇸 Englewood, Colorado, United States

Miami Cancer Institute at Baptist Health, Inc.; 🇺🇸 Miami, Florida, United States

Orlando Health; 🇺🇸 Orlando, Florida, United States

Moffitt Cancer Center; 🇺🇸 Tampa, Florida, United States

Northwestern University; 🇺🇸 Chicago, Illinois, United States

Massachusetts General Hospital; 🇺🇸 Boston, Massachusetts, United States

Dana-Farber Cancer Institute; 🇺🇸 Boston, Massachusetts, United States

Karmanos Cancer Institute; 🇺🇸 Detroit, Michigan, United States

Rutgers Cancer Institute of New Jersey; 🇺🇸 New Brunswick, New Jersey, United States

Laura & Isaac Perlmutter Cancer Center at NYU Langone Health; 🇺🇸 New York, New York, United States

Columbia University; 🇺🇸 New York, New York, United States

University of Rochester; 🇺🇸 Rochester, New York, United States

Lineberger Comprehensive Cancer Center; 🇺🇸 Chapel Hill, North Carolina, United States

Duke Cancer Institute, University Hospital; 🇺🇸 Durham, North Carolina, United States

University Hospitals Cleveland Medical Center; 🇺🇸 Cleveland, Ohio, United States

Cleveland Clinic Foundation; 🇺🇸 Cleveland, Ohio, United States

The Ohio State University James Comprehensive Cancer Center; 🇺🇸 Columbus, Ohio, United States

St Lukes University Health Network; 🇺🇸 Easton, Pennsylvania, United States

University Of Pittsburgh; 🇺🇸 Pittsburgh, Pennsylvania, United States

University of Tennessee Medical Center; 🇺🇸 Knoxville, Tennessee, United States

Tennessee Oncology - Centennial Clinic Location; 🇺🇸 Nashville, Tennessee, United States

Verdi Oncology; 🇺🇸 Nashville, Tennessee, United States

UT Southwestern Medical Center; 🇺🇸 Dallas, Texas, United States

Intermountain Medical Center; 🇺🇸 Murray, Utah, United States

University of Virginia Medical Center; 🇺🇸 Charlottesville, Virginia, United States

Fundacion Centro de Investigaciones para la Transformacion (CENIT); 🇦🇷 Caba, Buenos Aires, Argentina

Centro de Investigacion Pergamino; 🇦🇷 Pergamino, Buenos Aires, Argentina

Clinica Viedma S.A.; 🇦🇷 Viedma, Rio Negro, Argentina

Instituto de Oncologia de Rosario; 🇦🇷 Rosario, Santa Fe, Argentina

Centro Medico San Roque; 🇦🇷 San Miguel de Tucuman, Tucuman, Argentina

DIABAID - Instituto de Asistencia Integral en Diabetes; 🇦🇷 Caba, Argentina

Blacktown Cancer and Haematology Centre - Blacktown Hospital; 🇦🇺 Blacktown, New South Wales, Australia

Lismore Base Hospital; 🇦🇺 Lismore, New South Wales, Australia

Liverpool Hospital - Cancer Therapy Centre; 🇦🇺 Liverpool, New South Wales, Australia

Melanoma Institute of Australia; 🇦🇺 Wollstonecraft, New South Wales, Australia

Flinders Medical Centre; 🇦🇺 Bedford Park, South Australia, Australia

Calvary North Adelaide Hospital; 🇦🇺 North Adelaide, South Australia, Australia

Eastern Health; 🇦🇺 Box Hill, Victoria, Australia

Andrew Love Cancer Centre; 🇦🇺 Geelong, Victoria, Australia

Alfred Hospital; 🇦🇺 Melbourne, Victoria, Australia

One Clinical Research at Hollywood Private Hospital; 🇦🇺 Nedlands, Western Australia, Australia

Vitaz campus Sint-Niklaas Moerland; 🇧🇪 Sint-Niklaas, Oost-Vlaanderen, Belgium

AZ Groeninge; 🇧🇪 Kortrijk, West-Vlaanderen, Belgium

LTD New Hospitals; 🇬🇪 Tbilisi, Georgia

Cliniques Universitaires Saint-Luc; 🇧🇪 Bruxelles, Belgium

Hospital das Clinicas da Universidade Federal de Minas Gerais; 🇧🇷 Belo Horizonte, Minas Gerais, Brazil

Liga Paranaense de Combate ao Cancer - Hospital Erasto Gaertner; 🇧🇷 Curitiba, Parana, Brazil

INCA Instituto Nacional de Cancer; 🇧🇷 Santo Cristo, Rio De Janeiro, Brazil

Oncosite Centro De Pesquisa Em Oncologia; 🇧🇷 Ijui, Rio Grande Do Sul, Brazil

Instituto do Cancer em Hospital Sao Vicente de Paulo; 🇧🇷 Passo Fundo, Rio Grande Do Sul, Brazil

Hospital de Clinicas de Porto Alegre; 🇧🇷 Porto Alegre, Rio Grande Do Sul, Brazil

Hospital Moinhos de vento; 🇧🇷 Porto Alegre, Rio Grande Do Sul, Brazil

Centro de Pesquisa em Oncologia PUCRS; 🇧🇷 Porto Alegre, Rio Grande Do Sul, Brazil

Catarina Pesquisa Clinica; 🇧🇷 Itajai, Santa Catarina, Brazil

Instituto Joinvilense de Hematologia e Oncologia; 🇧🇷 Joinville, Santa Catarina, Brazil

Animi Unidade de Tratamento Oncologico; 🇧🇷 Lages, Santa Catarina, Brazil

Fundacao Pio XII - Hospital de Amor; 🇧🇷 Barretos, Sao Paulo, Brazil

Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto - Hospital de Base; 🇧🇷 Sao Jose do Rio Preto, Sao Paulo, Brazil

Unimed Sorocaba; 🇧🇷 Sorocaba, Sao Paulo, Brazil

Instituto COI; 🇧🇷 Rio de Janeiro, Brazil

Hemomed; 🇧🇷 Sao Paulo, Brazil

Hospital Sirio Libanes; 🇧🇷 Sao Paulo, Brazil

Sao Camilo Oncologia; 🇧🇷 Sao Paulo, Brazil

Dr. Everett Chalmers Hospital; 🇨🇦 Fredericton, New Brunswick, Canada

Royal Victoria Regional Health Centre; 🇨🇦 Barrie, Ontario, Canada

Sunnybrook Health Sciences Centre; 🇨🇦 Toronto, Ontario, Canada

Princess Margaret Cancer Centre; 🇨🇦 Toronto, Ontario, Canada

Clinica UC San Carlos de Apoquindo; 🇨🇱 Santiago, Region Metropolitana, Chile

Centro Oncologia de Precision Universidad Mayor; 🇨🇱 Santiago, Region Metropolitana, Chile

Oncocentro APYS; 🇨🇱 Vina del Mar, Valparaiso, Chile

Masaryk Memorial Cancer Institute; 🇨🇿 Brno, Brno Mesto, Czechia

University Hospital Hradec Kralove; 🇨🇿 Hradec Kralove, North Central Czech Republic, Czechia

University Hospital Ostrava; 🇨🇿 Ostrava, Czechia

Centre Georges Francois Leclerc; 🇫🇷 Dijon, Bourgogne, France

CHU-Dijon; 🇫🇷 Dijon, Burgundy, France

Besancon Regional University Hospital Center; 🇫🇷 Besancon, Doubs, France

Chu De Bordeaux; 🇫🇷 Bordeaux, Gironde, France

Institut Claudius Regaud, IUCT-Oncopole; 🇫🇷 Toulouse, Haute-Garonne, France

CHU de Lille; 🇫🇷 Lille, Hauts-de-France, France

Service de Dermatologie CHU Saint Eloi; 🇫🇷 Montpellier Cedex 5, Herault, France

Hopital Avicenne; 🇫🇷 Bobigny, Ile De France, France

Hospital Henri Mondor; 🇫🇷 Creteil, Ile De France, France

Saint Louis Hospital; 🇫🇷 Paris, Ile De France, France

Centre Hospitalier Universitaire Grenoble Alpes; 🇫🇷 La Tronche, Isere, France

Centre Francois Baclesse (CFB); 🇫🇷 Caen, Normandy, France

Centre Hospitalier Le Mans; 🇫🇷 Le Mans, Pays De La Loire, France

Nantes University Hospital; 🇫🇷 Nantes, Pays De La Loire, France

CHU Amiens-Picardie; 🇫🇷 Amiens, Picardie, France

Centre Hospitalier Universitaire De Nice Hopital De L Archet; 🇫🇷 Nice, France

Centre Hospitalier de Valence; 🇫🇷 Valence, France

Institut Gustave Roussy; 🇫🇷 Villejuif, France

Tbilisi State Medical University and Ingorokva High Medical Technology University Clinic; 🇬🇪 Tbilisi, Caucasus, Georgia

Cancer Center of Adjara; 🇬🇪 Batumi, Georgia

Acad.Fridon Todua Medical Center- Research Institute of Clinical Medicine; 🇬🇪 Tbilisi, Georgia

Israeli Georgian Medical Research Clinic Helsicore; 🇬🇪 Tbilisi, Georgia

JSC K. Eristavi National Center of Experimental and Clinical Surgery; 🇬🇪 Tbilisi, Georgia

TIM - Tbilisi Institute of Medicine; 🇬🇪 Tbilisi, Georgia

University Medical Center Mannheim; 🇩🇪 Mannheim, Baden Wurttemberg, Germany

University of Tuebingen; 🇩🇪 Tuebingen, Baden Wurttemberg, Germany

University Hospital Augsburg; 🇩🇪 Augsburg, Bavaria, Germany

Dermatology Erlangen; 🇩🇪 Erlangen, Bavaria, Germany

University Hospital of Regensburg; 🇩🇪 Regensburg, Bavaria, Germany

LMU Klinikum; 🇩🇪 Munich, Bayern, Germany

Klinikum Darmstadt GmbH; 🇩🇪 Darmstadt, Hessen, Germany

University Clinic Frankfurt; 🇩🇪 Frankfurt, Hessen, Germany

University Medical Center Goettingen; 🇩🇪 Gottingen, Lower Saxony, Germany

Helios Kliniken Schwerin; 🇩🇪 Schwerin, Mecklenburg / Vorpommern, Germany

University Hospital Muenster; 🇩🇪 Munster, North Rhine Westphalia, Germany

Universitatsklinikum Essen; 🇩🇪 Essen, North Rhine-Westphalia, Germany

Fachklinik Hornheide; 🇩🇪 Muenster, North Rhine-Westphalia, Germany

Ruhr University Bochum; 🇩🇪 Bochum, Northrhine Westphalia, Germany

Hautklinik; 🇩🇪 Ludwigshafen, Rheinland-Pfalz, Germany

Skin Cancer Center Harz; 🇩🇪 Quedlinburg, Saxony-Anhalt, Germany

University Hospital Dresden; 🇩🇪 Dresden, Saxony, Germany

University Hospital of Universitatsklinikum Schleswig Holstein (UKSH) Campus Kiel; 🇩🇪 Kiel, Schleswig Holstein, Germany

Universitatsklinikum Schleswig Holstein Campus Luebeck; 🇩🇪 Luebeck, Schleswig Holstein, Germany

Helios Klinikum Erfurt; 🇩🇪 Erfurt, Thuringia, Germany

Charite Universitaetsmedizin Berlin; 🇩🇪 Berlin, Germany

Klinikum Bremen Ost; 🇩🇪 Bremen, Germany

National and Kapodistrian University of Athens; 🇬🇷 Athens, Attica, Greece

Metropolitan Hospital; 🇬🇷 Neo Faliro, Attica, Greece

Ongology Theageneio Thessaloniki; 🇬🇷 Thessaloniki, Greece

Galway University Hospital; 🇮🇪 Galway, Connacht, Ireland

Cork University Hospital; 🇮🇪 Cork, Ireland

Beaumont Hospital; 🇮🇪 Dublin, Ireland

St Vincents University Hospital; 🇮🇪 Dublin, Ireland

Haemek Medical Center; 🇮🇱 Afula, Northern District, Israel

Hadassah Medical Organization; 🇮🇱 Jerusalem, Israel

Sheba Medical Center; 🇮🇱 Tel Hashomer, Israel

Clinica Oncologica, AOU Riuniti Ancona; 🇮🇹 Ancona, An, Italy

U.O.C. Oncologia Medica ed Ematologia (U.O.C Medical Oncology and Hematology); 🇮🇹 Naples, Campania, Italy

Istituto Romagnolo per lo Studio dei Tumori (IRST); 🇮🇹 Meldola, Forli Cesena, Italy

Istituto Clinico Humanitas; 🇮🇹 Milan, Lombardy, Italy

Istituto dei Tumori; 🇮🇹 Bari, Italy

Azienda Ospedaliera Santa Croce i Carle; 🇮🇹 Cuneo, Italy

Istituto Europeo di Oncologia; 🇮🇹 Milano, Italy

Instituto Nazionale Tumori Fondazione Giovanni Pascale; 🇮🇹 Naples, Italy

University of Perugia; 🇮🇹 Perugia, Italy

Fondazione Policlinico Universitrio a. Gemelli - IRCCS; 🇮🇹 Rome, Italy

Campus Bio-Medico di Roma; 🇮🇹 Rome, Italy

Istituto Dermopatico dell'Immacolata; 🇮🇹 Rome, Italy

Santa Chiara Hospital; 🇮🇹 Trento, Italy

Azienda Sanitaria Universitaria del Friuli Centrale; 🇮🇹 Udine, Italy

Preparaciones Oncologica SC; 🇲🇽 Leon, Guanajuato, Mexico

Antiguo Hospital Civil de Guadalajara Fray Antonio Alcalde; 🇲🇽 Guadalajara, Jalisco, Mexico

Pan American Clinical Research; 🇲🇽 Guadalajara, Jalisco, Mexico

iCan Oncology; 🇲🇽 Monterrey, Nuevo Leon, Mexico

Neurociencias Estudios Clinicos SC; 🇲🇽 Culiacan, Sinaloa, Mexico

Centro De Atencion E Investigacion Clinica En Oncologia SCP; 🇲🇽 Merida, Yucatan, Mexico

Faicic Centro de Investigacion Clinica de Veracruz; 🇲🇽 Veracruz, Mexico

Mazowiecki Szpital Wojewodzki, Siedleckie Centrum Onkologii; 🇵🇱 Siedlce, Mazxowieckie, Poland

Copernicus Podmiot Leczniczy Sp. z o.o.Wojewodzie Centrum Onkologii; 🇵🇱 Gdansk, Pomorskie, Poland

Wojewodzki Szpital Specjalistyczny im. Janusza Korczaka w Słupsku Sp. z o.o.; 🇵🇱 Slupsk, Pomorskie, Poland

Poznan University of Meidcla Science; 🇵🇱 Poznan, Wielkopolska, Poland

Institute of Oncology Bucharest; 🇷🇴 Bucharest, Bucuresti, Romania

Radiotherapy Center Cluj; 🇷🇴 Floresti, Cluj County, Romania

Cardiomed; 🇷🇴 Cluj-Napoca, Cluj, Romania

Institute of Oncology Prof. Dr Ion Chirircuta; 🇷🇴 Cluj-Napoca, Cluj, Romania

Sfantul Nectarie Oncology Center; 🇷🇴 Craiova, Dolj, Romania

Oncocenter Oncologie Clinica S.R.L; 🇷🇴 Timisoara, Timis, Romania

Oncomed; 🇷🇴 Timisoara, Timis, Romania

Centrul De Oncologie Euroclinic; 🇷🇴 Iasi, Romania

The Medical Oncology Centre of Rosebank; 🇿🇦 Johannesburg, Gauteng, South Africa

Wilgers Oncology Centre; 🇿🇦 Pretoria, Gauteng, South Africa

Groote Schuur Hospital; 🇿🇦 Cape Town, Western Cape, South Africa

Cape Town Oncology Trials; 🇿🇦 Kraaifontein, Western Cape, South Africa

Hospital Universitario Central De Asturias; 🇪🇸 Oviedo, Asturias, Spain

H. Germans Trias i Pujol, ICO-Badalona; 🇪🇸 Badalona, Barcelona, Spain

Hospital Universitario Marques de Valdecilla; 🇪🇸 Santander, Cantabria, Spain

Instituto Oncologico Dr Rosell Hospital Universitari Quiron Dexeus Location; 🇪🇸 Barcelona, Catalunya, Spain

Hospital Vall d'Hebron; 🇪🇸 Barcelona, Spain

Hospital Clinic de Barcelona; 🇪🇸 Barcelona, Spain

Catalan Institute of Oncology (ICO) Hospitalet; 🇪🇸 Barcelona, Spain

Hospital Universitario Virgen de las Nieves; 🇪🇸 Granada, Spain

Hospital Universitario Lucus Augusti; 🇪🇸 Lugo, Spain

Hospital General Universitario Gregorio Maranon; 🇪🇸 Madrid, Spain

Hospital Universitario 12 de Octubre Universidad Complutense de Madrid UCM; 🇪🇸 Madrid, Spain

Hospital Universitario La Pa<; 🇪🇸 Madrid, Spain

Centro Integral Oncologico HM Clara Campal; 🇪🇸 Madrid, Spain

Hospital Universitario Virgen Macarena; 🇪🇸 Seville, Spain

Gaziantep Medicalpoint Hospital; 🇹🇷 Gaziantep, Sehitkamil, Turkey

Gulhane Research And Training Hospital; 🇹🇷 Ankara, Turkey

Ozel Liv Hospital; 🇹🇷 Ankara, Turkey

Sbu Doctor Abdurrahman Yurtaslan Ankara Onkoloji Suam; 🇹🇷 Ankara, Turkey

Memorial Ankara Hospital; 🇹🇷 Ankara, Turkey

Trakya University; 🇹🇷 Edirne, Turkey

Istanbul University Cerrahpasa at Cerrahpasa Medical Faculty; 🇹🇷 Istanbul, Turkey

Istanbul Medeniyet University - Prof Dr Suleyman Yalcin Sehir Hospital; 🇹🇷 Istanbul, Turkey

Royal Devon and Exeter Hospital NHS Trust; 🇬🇧 Exeter, Devon, United Kingdom

Edinburgh Cancer Centre; 🇬🇧 Edinburgh, Lothian, United Kingdom

Bristol Haematology And Oncology Centre (BHOC) - Bristol Cancer Institute; 🇬🇧 Bristol, Somerset, United Kingdom

The Royal Marsden NHS Foundation Trust; 🇬🇧 Sutton, Surrey, United Kingdom

University Hospital Coventry and Warwickshire Nhs Trust; 🇬🇧 Coventry, West Midlands, United Kingdom

Saint Bartholomew's Hospital; 🇬🇧 London, United Kingdom

University College London Hospitals; 🇬🇧 London, United Kingdom

The Christie; 🇬🇧 Manchester, United Kingdom

Taunton and Somerset NHS Foundation Trust; 🇬🇧 Taunton, United Kingdom